Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of TAK-931 in advanced solid tumors
jRCT2080223145Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simurosertib in Nonhematologic neoplasms, sponsored by Takeda. Primary endpoints: Safety and tolerability of TAK-931 and Pharmacokinetics of TAK-931. Started Mar 2016; status: completed.
02
Drugs
simurosertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080223145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223145.